Filing search / Cartesian Therapeutics, Inc. / "Safety"

8-K

EX-99.1

RNAC Cartesian Therapeutics, Inc.

3 Mar 25

Regulation FD Disclosure

6:59am

reference to the Company’s product candidates’ potential benefits, safety, or efficacy is based on observations from ongoing clinical research … in participants without exposure to prior biologic therapy Safety profile continues to support outpatient administration Planned Phase 3 AURORA study design

8-K

EX-99.1

RNAC Cartesian Therapeutics, Inc.

13 Jan 25

Regulation FD Disclosure

7:04am

potential benefits, safety, or efficacy is based on observations from ongoing clinical research and should not be interpreted as definitive clinical … of ≥3 points at Month 4, relative to placebo SECONDARY OBJECTIVES Proportion of participants with MGC improvement of ≥4 points at Month 4 Safety

8-K

EX-99.2

RNAC Cartesian Therapeutics, Inc.

13 Jan 25

Regulation FD Disclosure

7:04am

-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared … to assess the safety, tolerability and clinical activity of outpatient Descartes-08 administration without preconditioning chemotherapy in patients

424B7

RNAC Cartesian Therapeutics, Inc.

8 Jan 25

Prospectus with selling stockholder info

4:38pm

and clinical development activities; the efficacy and safety profile of our product candidates; the potential therapeutic benefits and economic value

424B7

RNAC Cartesian Therapeutics, Inc.

8 Jan 25

Prospectus with selling stockholder info

4:33pm

operations; our market size and our potential growth opportunities; our preclinical and clinical development activities; the efficacy and safety

424B3

9obuoddp

8 Jan 25

Prospectus supplement

4:30pm

8-K

EX-99.2

4lpd3ck

3 Dec 24

Regulation FD Disclosure

6:03am

8-K

8i3d10nmre e8x

3 Dec 24

Regulation FD Disclosure

6:03am

8-K

EX-99.1

mpoh7wsxo8wjqe0fz jh

3 Dec 24

Regulation FD Disclosure

6:03am

8-K

EX-99.1

4lhljhqf

7 Nov 24

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

7:06am

424B7

remg8dlx2 8dt0o6

1 Oct 24

Prospectus with selling stockholder info

4:36pm

8-K

EX-99.2

4fe6q3lwcth4157a8x

8 Aug 24

Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

7:04am